Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

NCT05377788 · clinicaltrials.gov ↗

UNKNOWN

Status

900

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
EGFR T790M

Interventions

DRUG: Lazertinib

Sponsor

Samsung Medical Center